In PSC with Colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment

• Verfasst von: Rudolph, Georgia [VerfasserIn]
• Verfasst von: Gotthardt, Daniel [VerfasserIn]
• Verfasst von: Kloeters-Plachky, P. [VerfasserIn]
• Verfasst von: Kulaksiz, H. [VerfasserIn]
• Verfasst von: Schirmacher, Peter [VerfasserIn]
• Verfasst von: Stiehl, Adolf [VerfasserIn]
• Titel: In PSC with Colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment
• Verf.angabe: G. Rudolph, D.N. Gotthardt, P. Kloeters-Plachky, H. Kulaksiz, P. Schirmacher, A. Stiehl
• E-Jahr: 2011
• Jahr: 09 June 2011
• Umfang: 7 S.
• Fussnoten: Gesehen am 21.09.2022
• Titel Quelle: Enthalten in: Digestive diseases and sciences
• Ort Quelle: Dordrecht : Springer Science + Business Media B.V., 1934
• Jahr Quelle: 2011
• Band/Heft Quelle: 56(2011), 12, Seite 3624-3630
• ISSN Quelle: 1573-2568
• DOI: doi:10.1007/s10620-011-1763-2
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Erscheint auch als : Druck-Ausgabe: Rudolph, Georgia: In PSC with Colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. - 2011
• Sach-SW: Colonic carcinomas
• Sach-SW: Inflammatory bowel disease
• Sach-SW: Sclerosing cholangitis
• Sach-SW: Ursodeoxycholic acid
• K10plus-PPN: 181720548X

Abstract

Background: Patients with PSC and IBD have a high incidence of colonic carcinomas (CRC), and the annual incidence of CRC increases with duration of disease. UDCA treatment has been suggested to reduce colonic dysplasias and carcinomas. Aims: The annual incidence of colorectal carcinomas after long-term UDCA treatment was studied. Methods: Patients included in a prospective study on the outcome after ursodeoxycholic acid (UDCA) treatment were evaluated. Results: A total of 120 of 171 PSC patients included had IBD (108 UC and 12 CD). All patients were treated with UDCA for a median time of 6.7 years. Seven patients with PSC and IBD developed a CRC yielding a prevalence of 5.8%. In years 0–3 (n = 120) after the start of UDCA, the annual incidence rate of CRC was 0.62/100 patient years; in years 3–6 (n = 93) it increased to 1.28 and decreased thereafter in years 6–9 (n = 67) to 1.17, then in years 9–12 (n = 42) to 0 and after >12 years (n = 24) it remained 0. In PSC with IBD, Kaplan–Meier estimate of CRC formation increased with time in the first years of treatment and reached a plateau after 9 years; after treatment for ≥9 years, no further CRC were observed. Conclusion: After the start of UDCA, the annual incidence of CRC increased up to 6 years and subsequently decreased. In PSC with IBD treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.